2025年，产品收入为377.70亿元，上年同期产品收入为269.94亿元，产品收入的增长主要得益于百悦泽 ®(泽布替尼)，以及安进公司授权产品和百泽安®(替雷利珠单抗)的销售增长。 2025年，百悦泽®全球销 售额总计280.67亿元，同比增长48.8%，已在BTK抑制剂领域稳固确立全球领导者的地位。 报告期内，公司营业收入增加40.4%，主要得益于百悦泽®，以及安进公司授权产品和百泽安®的销售 增长。报告期内，公司营业利润、利润总额、归属于母公司所有者的净利润、归属于母公司所有者的扣 除非经常性损益的净利润和基本每股收益较上年同期相比实现盈利，主要得益于产品收入增长和费用管 理推动的经营效率提升。 智通财经APP讯，百济神州(688235.SH)披露2025年度业绩快报，报告期内，公司营业总收入为382.05亿 元，同比上升40.4%;归属于母公司所有者的净利润14.22亿元，同比扭亏为盈。 ...

Core Viewpoint - BeiGene (ONC.US) reported a strong performance in Q3, with revenue exceeding 10 billion RMB, leading to an upward revision of its 2025 revenue guidance [1] Financial Performance - In Q3, BeiGene's revenue reached 10.077 billion RMB, a year-on-year increase of 41.1% [1] - Product revenue was 9.954 billion RMB, growing by 40.6% year-on-year [1] - For the first three quarters of 2025, revenue totaled 27.595 billion RMB, up 44.2% compared to the previous year [1] - The company's product revenue for the same period was 27.314 billion RMB, reflecting a 43.9% year-on-year increase [1] - Net profit attributable to the parent company was 1.139 billion RMB, driven by significant product revenue growth and improved cost management [1] Guidance Revision - Due to strong Q3 performance, BeiGene revised its 2025 full-year revenue guidance from a range of 35.8 billion to 38.1 billion RMB to a new range of 36.2 billion to 38.1 billion RMB [1] Market Position and Efficiency - The revenue growth is primarily attributed to the leading position of BeiGene's product, Brukinsa (Zebutinib), in the U.S. market, along with its ongoing expansion in Europe and other key global markets [1] - Research and development expenses, as well as selling and administrative expenses, are expected to narrow to a range of 29.5 billion to 30.9 billion RMB, reflecting prudent investment strategies that enhance revenue and pipeline growth [1]